AKTS · Aktis Oncology, Inc. · Stock research

Current Thesis

The narrative being bought is a radioligand-therapy (RLT) pure-play, freshly public, re-rating on a sell-side coverage wave rather than on data. Aktis IPO'd in January 2026 (priced $18.00, first biotech IPO of the year) and is up ~64% to ~$29.44. The accelerant over the past month is the post-quiet-period initiation cluster Raymond James Strong Buy PT $40 (2026-06-16) and HC Wainwright Buy PT raised to $35 (2026-06-02) stacked on top of an Eli Lilly halo (up-to-$1.1B collaboration, $100M IPO anchor). The leg is real and ACCELERATING, but the accelerant is coverage and flow, not clinical readouts: the first efficacy data is Q1 2027, and an IPO lock-up unlock lands within the next two weeks. A young, narrative-driven uptrend with a known near-term supply event.

Bullish and bearish views on Aktis Oncology, Inc.

The model's bull view on Aktis Oncology, Inc. (AKTS), in brief: Radioligand therapy is the M&A-validated oncology narrative: Novartis Pluvicto commercial success, BMS/RayzeBio ($4.1B, 2024), Lilly/Point Biopharma, AstraZeneca/Fusion AKTS is the newest listed pure-play in the cohort. The bear view: No efficacy data until Q1 2027 (AKY-1189 Phase 1b preliminary) and 2027 (AKY-2519 mCRPC) nothing fundamental drives the tape for 6+ months; this is platform/theme narrative only. Both cases follow in full.

Bull Case

• Radioligand therapy is the M&A-validated oncology narrative: Novartis Pluvicto commercial success, BMS/RayzeBio ($4.1B, 2024), Lilly/Point Biopharma, AstraZeneca/Fusion AKTS is the newest listed pure-play in the cohort.
• Eli Lilly anchored the IPO with $100M (~one-third of shares sold) and runs an up-to-$1.1B collaboration the strongest strategic validation a pre-data biotech can carry (per IPO disclosure, January 2026).
• Sell-side coverage accelerating: Raymond James Strong Buy, PT $40, analyst Christopher Raymond (2026-06-16); HC Wainwright Buy, PT raised to $35 (2026-06-02); four-plus initiations clustered the week of 2026-06-16 all targets sit above the current ~$29.44.
• Fortress balance sheet: $538.5M cash and marketable securities at 2026-03-31, runway guided "into 2029" no dilution pressure before the 2027 data.
• Differentiated miniprotein platform carrying alpha-emitter payloads; lead AKY-1189 (Nectin-4) holds FDA Fast Track in metastatic urothelial cancer.
• Two clinical shots on goal: AKY-1189 Phase 1b enrolling across multiple tumor types; AKY-2519 (B7-H3) Phase 1b mCRPC initiated mid-2026 with a basket trial planned H2 2026.

Bear Case

• No efficacy data until Q1 2027 (AKY-1189 Phase 1b preliminary) and 2027 (AKY-2519 mCRPC) nothing fundamental drives the tape for 6+ months; this is platform/theme narrative only.
• IPO lock-up (~180 days from the January 2026 offering, est. ~2026-07-07 to 2026-07-11) unlocks insider and Lilly supply into a ~55M-share float the standard freshly-IPO'd biotech overhang, and it hits within days.
• Extended: +64% from the $18.00 IPO, $29.44 against the $33.53 52-week high; only ~20–36% upside remains to the already-public $35–$40 targets.
• Burn rising: Q1 2026 net loss $18.3M vs $15.0M a year earlier (reported 2026-05-11); multi-year pre-revenue with binary clinical risk.
• The RLT theme itself is maturing the headline M&A re-rating already happened in 2024–2025; AKTS rides the tail of an established narrative.
• Pre-data clinical biotech: a single Phase 1b safety signal in 2027 can halve the stock, and actinium-225 alpha-emitter supply is a known sector bottleneck.

Setup & Price Structure

• Price ~$29.44 (2026-06-26, close), -5.49% on the day; after-hours $30.02. Market cap ~$1.63B on ~55.3M shares.
• 52-week range $14.72–$33.53; trades in the upper third, just off the high.
• The entire chart is five months old priced $18.00, first trade ~2026-01-09 so there is no multi-year support, only a young post-IPO trend.
• The June initiation cluster (HCW 06-02, RJ 06-16) coincided with the push toward $33.50 and the subsequent fade back to ~$29.
• ACCELERATING on flow, but structurally a thin, recently-public uptrend that has to absorb a lock-up unlock before it can prove itself.

Catalyst Calendar (next 30 days)

• Out of window: Q2 2026 results (quarter ended 06-30) expected ~early-to-mid August 2026; AKY-1189 preliminary Phase 1b data Q1 2027; AKY-2519 mCRPC preliminary data 2027.

Elapsed catalysts

• ~2026-07-07 to 2026-07-11 (est.): 180-day IPO lock-up expiration insider/Lilly share unlock. The dominant near-term price driver and effectively the binary for the next month. _(passed 4d ago)_
• Ongoing: scope for additional sell-side initiations while the post-IPO coverage window stays open (4+ already clustered the week of 2026-06-16). _(passed 29d ago)_

What Would Change Our Mind

• A weekly close below $24 negates the post-IPO uptrend and the June coverage-wave breakout the signal that lock-up supply has overwhelmed the narrative bid.
• Lock-up expiration passing with visible insider distribution and a failure to reclaim $30 → theme bid exhausted.
• Radioligand therapy rolling to SATURATED with no fresh M&A or clinical validation before the 2027 readouts.
• Constructive flip: a clean hold of the low-$20s through the unlock plus a reclaim of $33.53 on expanding volume re-arms the trend.

Correlation Notes

• Moves with the radiopharma cohort: Lantheus (LNTH), Telix (TLX), Perspective Therapeutics (CATX), and the embedded RLT franchises at Novartis (Pluvicto), BMS (RayzeBio), Lilly (Point), AstraZeneca (Fusion).
• High beta to Eli Lilly (LLY) headlines given the up-to-$1.1B partnership Lilly oncology/RLT commentary reads through directly.
• XBI/small-cap-biotech risk-appetite sensitive: a pre-data, recently-IPO'd name is a high-beta expression of biotech sentiment and rate moves.
• Ticker disambiguation: AKTS formerly traded as Akoustis Technologies (RF/analog semiconductor filters), an unrelated and now-defunct company no read-through to this name.